TC-99M-LABELED MONOCLONAL-ANTIBODIES FOR IMMUNOSCINTIGRAPHY - SIMPLIFIED PREPARATION AND EVALUATION

被引:45
作者
THAKUR, ML
DEFULVIO, JD
机构
[1] Thomas Jefferson University Hospital, Department of Radiation Oncology and Nuclear Medicine, Philadelphia, PA 19107
关键词
IMMUNOSCINTIGRAPHY; TC-99M LABELING; ASCORBIC ACID; MONOCLONAL ANTIBODY;
D O I
10.1016/0022-1759(91)90027-D
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Ascorbic acid incubated with monoclonal antibodies (22-degrees-C, 60 min, pH 6.5) at a molar ratio of 3500:1, reduced 2.7 +/- 0.2% of the available disulfides to sulfhydryl groups that strongly bind 99mTc, and provided greater than 95% labeling efficiency for several IgM, IgG and F(ab')2 antibodies. The colloid formation was consistently less than 3% and the stability of the tracer when challenged with DTPA and cysteine was excellent. The immunospecificity of labeled antibodies as determined by immobilized specific antigen assay was 84 +/- 1% for IgM and 82.6 +/- 1.1% for IgG antibodies. For in vivo evaluation in mice bearing experimental abscesses and tumors, corresponding I-125-labeled antibodies served as controls. The liver uptake was similar (P = 0.76 and P = 0.12) for Tc-99m or I-125 labeled antinuclear antibody TNT-1 in mice bearing abscesses as well as for Tc-99m-TNT-1-F(ab')2 and I-125-TNT-1-F(ab')2 in mice bearing tumors. Higher but statistically insignificant (P = 0.08, 0.18, and 0.73) urinary excretion was noted for Tc-99m-antibodies. For corresponding Tc-99m- and I-125-labeled antibodies, the abscess to muscle ratios (3.3 +/- 0.5 vs. 3.4 +/- 0.8) and tumor to muscle ratios (10.04 +/- 4.4 vs. 10.54 +/- 3.0) were similar. The high Tc-99m-TNT-1-F(ab')2 uptake permitted excellent scintigraphic visualization of tumors whereas the nonspecific Tc-99m-HSA did not (tumor/muscle ratio: 2.4 +/- 0.3). This method is simple, reliable, and adaptable to an instant labeling technique.
引用
收藏
页码:217 / 224
页数:8
相关论文
共 22 条
[1]  
DELROSARIO RB, 1989, NUCL MED BIOL, V6, P525
[2]  
ECKELMAN WC, 1990, CANCER RES, V50, pS780
[3]  
FRITZBERG AR, 1986, J NUCL MED, V27, P957
[4]  
HAWKINS EB, 1990, RADIOPHARMACOL, V3, P17
[5]  
HOFFMAN T, 1990, CANCER RES, V50, pS1490
[6]  
LARSON SM, 1990, CANCER RES S, V50, P8925
[7]  
MATHER SJ, 1990, J NUCL MED, V31, P682
[8]  
ORDER SE, 1990, CANCER RES, V50, pS1011
[9]   THE LABELING OF HIGH-AFFINITY SITES OF ANTIBODIES WITH TC-99M [J].
PAIK, CH ;
PHAN, LNB ;
HONG, JJ ;
SAHAMI, MS ;
HEALD, SC ;
REBA, RC ;
STEIGMAN, J ;
ECKELMAN, WC .
INTERNATIONAL JOURNAL OF NUCLEAR MEDICINE & BIOLOGY, 1985, 12 (01) :3-8
[10]  
PAK K Y, 1989, Journal of Nuclear Medicine, V30, P793